d2-like

ONC206, an analogue of the TRAIL inducer ONC201, acts as a selective antagonist of the D2-like dopamine receptors (DRD2 3 4) at nanomolar concentrations and possesses broad-spectrum anti-tumor activity.

SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2 5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia.

Cabergoline (FCE-21336) is an ergot derived-dopamine D2-like receptor agonist. It has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).Cabergoline permits rapid and effective hormonal and tumor control by normalizing prolactin-producing pituitary adenomas levels.

Tipepidine hydrochloride is a reversible inhibitor of dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) (IC50: 7.0 μM), with antidepressant-like effect.

Bifeprunox is a potent partial agonist of dopamine D2-like and 5-HT1A receptor (pEC50: 6.37 for hippocampus 5-HT1A; pKis: 7.19 and 8.83 for cortex 5-HT1A and striatum D2). It is an antipsychotic for the research of schizophrenia.

SEP-363856 hydrochloride (SEP-856 hydrochloride) is an orally active, CNS-active psychotropic agent with a unique non-D2 5-HT2A mechanism of action, demonstrating antipsychotic-like effects and potential for schizophrenia treatment.

SB269652 is the pioneering drug-like allosteric modulator of the dopamine D2 receptor.

ECPLA is an LSD analog and a potent 5-HT2A agonist (EC50 of 14.6 nM), capable of stimulating Gq-mediated calcium flux. It exhibits high affinity for most serotonin receptors, α2-adrenergic receptors, and D2-like dopamine receptors.

N-Methylspiroperidol is a D2 receptor antagonist. This compound can be labeled as [18F]N-Methylspiroperidol, which allows for the investigation of its interaction with 5-HT2C receptors via PET (positron emission tomography), as well as examining the competition and impact of neurotransmitters like dopamine on these receptors.

2-CMDO is a Dopamine D2-like receptor antagonist.

Nemonapride is a dopamine D2-like receptor antagonist.

5-HT2A serotonin and selective D2-like dopamine receptor antagonist

Quinpirole dihydrochloride is an agonist of the D2-like dopamine receptor.

Eticlopride, an antipsychotic, is a Selective dopamine D2 D3 receptor antagonist (Ki: 0.5 0.16 nM).

Tipepidine is a non-narcotic antitussive with an antidepressant-like effect. Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK) ) (IC 50 = 7.0 μM) and subsequently activates VTA dopamine neurons.

NAZ2329 is the first cell-permeable inhibitor of the R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), which is a variant and preferentially inhibits PTPRZ (IC50=7.5 μM for hPTPRZ1) and PTPRG (IC50=4.8 μM for hPTPRG) compared to other PTPs. NAZ2329 inhibited the tumor growth of glioblastoma cells and exhibited stem cell-like properties compared to the whole (D1 + D2) fragment of PTPRZ.

Dioleoylphosphatidylglycerol (DOPG), a naturally occurring phospholipid, is synthesized through the action of aquaporin 3 (AQP3) and phospholipase D2 (PLD2). It functions to suppress the production of inflammatory mediators by macrophages triggered by the activation of toll-like receptor 2 (TLR2) by heat shock protein B4 (HSPB4) [1].

MeSeI exhibits weak inhibitory activity against monoamine oxidases MAO-A and MAO-B, with IC50 values of 198.8 µM. It modulates dopamine receptor D2 (dopamine receptorD2) and norepinephrine receptors α2, β1 (norepinephrine receptor α2, β1), displaying antidepressant-like effects in mice. Additionally, MeSeI is orally active.